Evexomostat is under clinical development by SynDevRx and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Evexomostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evexomostat (SDX-7320) is under development for the treatment of solid tumors includes metastatic breast cancer, HER2 negative breast cancer, non-small cell lung cancer, hepatocellular carcinoma, triple negative breast cancer, metastatic colorectal cancer, melanoma, metastatic prostate cancer, metabolic diseases, liver cancer, metastatic lung cancer, obesity-accelerated growth of multiple myeloma and idiopathic pulmonary fibrosis. It is administered subcutaneously. The drug candidate is a fumagillol derivative which targets MetAP2. SDX-7320 combines two functional parts, a MetAP2 inhibitor coupled to a bio-compatible, stable polymer backbone, clinically proven to improve safety, bio-distribution, tumor targeting, and pharmacokinetics of the attached active drug.
SynDevRx (SDX) is a drug development company that develops treatments for cancer and metabolic dysfunction. The company offers lead compound SDX-7320, that helps in identifying solid tumors, 2nd line breast cancer, hepatocellular carcinoma, and idiopathic pulmonary fibrosis. Its services include clinical trial design and management, process development, chemistry, manufacturing and controls, toxicology, pharmacology, and regulatory affairs. SDX offers SDX-7195 for the treatment of metabolic diseases. It conducts clinical trials for developing new therapies to improve future treatment for various cancer types and conditions associated with metabolic dysfunction. The company partners with clinical oncologists, researchers, professors and medical professional to develop drugs. SDX is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Evexomostat’s drug-specific PTSR and LoA scores, buy the report here.